The cornerstone of biocatalysis lies in directed evolution, a method where scientists simulate natural selection in the lab by generating large libraries of enzymes with varied genetic sequences. These variants are then systematically screened to pinpoint those with the most desirable catalytic properties. While creating large, genetically diverse enzyme libraries is now routine, the Achilles’ heel of this process has consistently been the screening phase. Analyzing the molecular products made by thousands, sometimes tens of thousands, of enzyme candidates has historically been a painstakingly slow and resource-intensive bottleneck, delaying discovery timelines and inflating costs.

At the heart of the new approach is the enhancement of mass spectrometry, often referred to as “the world’s most expensive balance.” This analytical powerhouse measures the mass-to-charge ratio of molecules with remarkable precision, allowing scientists to deduce chemical compositions rapidly. However, traditional mass spectrometry struggles when confronted with molecules that share the exact molecular weight but differ in their three-dimensional spatial arrangements — a phenomenon known as chirality. These structural nuances, distinguishing mirror-image molecules akin to left and right hands, have profound implications in biology and pharmacology, where one isomer might be therapeutically beneficial while its counterpart could be inactive or even harmful.

The UC Santa Cruz researchers have devised a method that transcends this limitation by incorporating additional measurements that capture molecular shape and size. This hybrid analytical strategy empowers their platform to discriminate isomeric molecules efficiently, bypassing the need for time-consuming and cumbersome procedures previously required to differentiate chirality. Such capacity is pivotal when targeting natural products and pharmaceutical intermediates where structural specificity directly correlates with bioactivity and safety.

Their proof-of-concept application centers on kainic acid, a neuroactive compound naturally sourced from certain seaweed species. Kainic acid has long been valued in neuropharmacology for its selective activation of ionotropic glutamate receptors, which has made it an indispensable tool for studying neurological processes and diseases such as epilepsy. Traditionally, kainic acid was extracted directly from marine biomass, a process fraught with sustainability issues and supply constraints, exacerbated by overharvesting concerns that have previously threatened the ecological balance of those seaweed populations.

Synthetic chemistry has made numerous attempts to replicate kainic acid, with over seventy different synthetic routes documented. Unfortunately, despite this considerable effort, existing chemical syntheses remain lengthy, involving multiple reaction steps — often six to eleven in number — making scalable production both cumbersome and cost-prohibitive. This constrained access has limited kainic acid’s broader potential applications in research and therapeutic development.

Conversely, the enzymatic manufacturing pathway, initially pioneered by the Scripps Institution of Oceanography at UC San Diego and further refined at UC Santa Cruz, employs a remarkably efficient approach. This method begins with a chemically synthesized precursor, which is then converted into kainic acid through a single enzymatic reaction that effectively forms the molecule’s signature pyrrolidine ring system. Such biocatalytic efficiency reduces the synthesis timeline dramatically and opens doors to sustainable, large-scale production of kainoids and related neurochemicals.

A major contributor to this breakthrough is the synergistic collaboration between the Sanchez and McKinnie laboratories at UC Santa Cruz. The Sanchez Lab brought deep expertise in mass spectrometry and chemical analysis, while the McKinnie Lab contributed profound knowledge in enzyme discovery and organic synthesis. This interdisciplinary partnership facilitated the development of a screening paradigm that preserves and leverages three-dimensional structural information, enabling accurate distinction between molecular isomers during high-throughput screening assays.

Robert Shepherd, the principal graduate student leading this research, emphasizes the transformative nature of blending expertise across scientific domains to solve longstanding challenges in biocatalytic screening. He remarks on the invigorating research environment fostered by this collaborative effort, where convergence of diverse skills and perspectives catalyzes innovative solutions that transcend traditional disciplinary boundaries. This shared passion has fueled remarkable progress toward creating more potent, selective enzymes capable of synthesizing valuable compounds with reduced environmental footprints.

Beyond graduate students, the project enlisted the talents of postdoctoral fellows and undergraduates, with strong support from the Science Division’s STEM diversity programs. The team’s dedication was sustained by funding from the National Institutes of Health, via an R21 grant tailored to incentivize pioneering, high-impact research efforts still in early conceptual phases. This financial backing underscores the broader scientific community’s recognition of the potential impact that rapid and precise enzyme screening can have on drug discovery and green chemistry.

The promising platform outlined in this study sets a roadmap not only for accelerating enzyme evolution but also for democratizing access to powerful screening technologies, making them more accessible to a wide range of laboratories. By enabling researchers to swiftly navigate through vast enzyme variant libraries with improved accuracy and speed, the technology encourages deeper exploration of enzyme functions, paving the way for discovering novel catalysts and therapeutic agents.

In summary, the UC Santa Cruz team has delivered a technically sophisticated yet practically impactful tool that could reshape how chemists and biochemists approach the development of enzyme-driven synthesis. By surmounting longstanding obstacles in characterizing molecular isomers quickly and efficiently, this advancement significantly enhances the toolbox for biocatalysis and drug discovery. The marriage of advanced mass spectrometry with smart decision frameworks offers a powerful example of how innovation at disciplinary intersections can drive science forward with tangible societal benefits.

Article Title: A High-Throughput Biocatalytic Platform for Screening Isomeric Kainoid Natural Products
News Publication Date: 5-Feb-2026
Web References: https://www.cell.com/cell-reports-physical-science/fulltext/S2666-3864(25)00691-5
References: 10.1016/j.xcrp.2025.103092
Image Credits: By Carolyn Lagatutta, UC Santa Cruz

Keywords: biocatalysis, directed evolution, mass spectrometry, enzyme screening, chirality, kainic acid, neuropharmacology, high-throughput assay, enzyme variants, molecular isomers, sustainable synthesis, UC Santa Cruz

Traditional drug development often hinges on the ability of small molecules to directly inhibit enzymatic activity or protein-protein interactions. However, many pathogenic proteins lack druggable pockets, rendering them refractory to classical inhibition. The field of targeted protein degradation circumvents this obstacle by co-opting the cell’s intrinsic protein quality control machinery to selectively eliminate target proteins. As such, molecules known as “degraders” recruit E3 ubiquitin ligases to the target protein, triggering ubiquitination and subsequent proteasomal degradation. While the concept is powerful, identifying effective degraders remains a significant bottleneck due to limitations in screening technologies and the structural complexity of induced-proximity interactions.

Addressing these challenges head-on, the DEFUSE platform redefines the screening paradigm by converting protein degradation into a phenotypic readout of cell survival. The technique ingeniously fuses the protein of interest to a rapid-acting, inducible death protein. In cells expressing this fusion construct, degradation of the target protein disrupts the death protein’s function, thereby rescuing the cell from induced apoptosis. Consequently, the survival of cells under selective pressure becomes an unequivocal indicator of effective targeted degradation. This switch from traditional biochemical assays to a survival-based, high-throughput cellular assay enables rapid and sensitive detection of functional degraders.

Applying DEFUSE to the oncoprotein SKP2, the researchers discovered a novel small molecule, SKPer1, that potently and selectively induces degradation of SKP2. SKP2 is a vital component of the SCF (SKP1-CUL1-F-box protein) E3 ligase complex and has been widely implicated in cancer pathogenesis through its regulation of cell cycle progression and degradation of tumor suppressors such as p27Kip1. Overexpression of SKP2 frequently correlates with poor prognosis in multiple malignancies, making it a highly attractive yet elusive therapeutic target. SKPer1’s ability to specifically eliminate SKP2 confirms the power of DEFUSE in unearthing potent molecular glues that prompt simultaneous interaction of SKP2 with the E3 ligase STUB1, culminating in targeted ubiquitination and proteasomal clearance.

Mechanistically, SKPer1 functions as an induced-proximity degrader, a subclass of targeted degraders that act by physically bridging the target protein with an E3 ligase that otherwise does not interact under normal cellular conditions. This strategy not only broadens the range of E3 ligases that can be harnessed for degradation but also exemplifies the subtleties of molecular glue chemistry in drug discovery. The study expands our understanding of induced proximity effects, demonstrating that carefully engineered small molecules can initiate protein-protein interactions previously uncharacterized, thereby reprogramming cellular ubiquitination pathways with high specificity.

The therapeutic implications of SKPer1 were rigorously validated both in vitro and in vivo. In cellular models, SKPer1 treatment led to a marked reduction in SKP2 protein levels accompanied by decreased proliferative capacity specifically in SKP2-expressing cancer cell lines. Importantly, this degradation translated to selective cytotoxicity, highlighting the molecule’s precision and minimal off-target effects. Animal studies corroborated these findings, where SKPer1 administration achieved significant tumor growth suppression with an encouraging safety profile. This preclinical success underscores SKPer1’s potential as a lead candidate for further drug development, offering hope for combating refractory cancers driven by SKP2 dysregulation.

Beyond the discovery of SKPer1, the DEFUSE platform unveiled an additional innovative insight: a ten-amino acid sequence derived from SKP2 can be leveraged as a modular degradation tag. This peptide sequence serves as a versatile handle that, when fused to other proteins, confers susceptibility to the SKPer1-induced degradation machinery. Such a tool represents a powerful new methodology for conditionally controlling protein stability, offering avenues for both basic research applications and therapeutic development, including the design of bespoke protein degradation systems tailored to diverse targets.

The imaging-based nature of DEFUSE is particularly compelling, as it allows rapid visualization and quantification of degradation events through fluorescence microscopy, enabling screens to be conducted efficiently on large chemical libraries. This contrasts with many existing approaches that rely on indirect or low-throughput assays, thus positioning DEFUSE as a scalable solution for accelerated drug discovery pipelines. The high sensitivity and specificity of the system ensure that identified hits are physiologically relevant degraders, increasing the likelihood of downstream translational success.

Furthermore, DEFUSE’s modular design is adaptable to any protein of interest, broadening its applicability across a spectrum of disease-related proteins. By harnessing different death effector domains, the method could be customized to optimize readouts in various cell types or contextual environments, thereby expanding the potential target space for induced-proximity degraders. In essence, DEFUSE represents a bridge between molecular biology innovation and chemical biology screening, providing a transformative toolkit to decode and exploit protein degradation pathways.

The discovery of SKPer1 also highlights the importance of E3 ligase diversity in degrader design. While many prototypical degraders utilize well-characterized E3 ligases such as cereblon or VHL, SKPer1’s recruitment of STUB1 uncovers new molecular relationships and underscores the therapeutic value of targeting underexplored components of the ubiquitin-proteasome system. This diversification could mitigate resistance mechanisms and expand degrader efficacy across different disease contexts.

Importantly, the study also emphasizes the relevance of induced-proximity pharmacology—where the small molecule acts as a molecular matchmaker rather than a conventional active site binder. This paradigm shift challenges traditional medicinal chemistry approaches and calls for a deeper integration of structural biology, proteomics, and chemical design to optimize molecular glue degraders. The findings from DEFUSE and SKPer1 thus provide critical proof-of-concept evidence for this promising therapeutic strategy.

Taken together, this work provides a blueprint for future efforts aiming to explore the vast “degradable” proteome. The convergence of innovative screening technology, mechanistic insights into induced proximity, and tangible therapeutic success propels the field of targeted protein degradation into a new era. As the scientific community continues to dissect the underlying biology and refine the chemical tools, approaches like DEFUSE could become standard in the drug discovery toolbox, accelerating the development of first-in-class therapies against challenging disease targets.

In conclusion, the development of the DEFUSE screening platform and the identification of SKPer1 as a potent degrader of the oncogenic SKP2 exemplify the transformative power of modern protein degradation technologies. By translating biochemical degradation events into a robust cell survival phenotype and harnessing induced-proximity effects, this study illuminates previously inaccessible facets of drug discovery. The integration of these advancements promises to redefine therapeutic intervention strategies for cancer and beyond, heralding a new wave of precision medicines tailored to manipulate the proteome at will.

This pioneering research not only expands the frontiers of targeted degradation but also sets a precedent for future high-throughput approaches that blend biological ingenuity with chemical innovation. As the global community strives to conquer disease at the molecular level, platforms like DEFUSE and discoveries like SKPer1 represent beacon technologies that will shape the landscape of precision oncology and molecular pharmacology for years to come.

Subject of Research: Targeted protein degradation technology and discovery of small-molecule degraders for oncogenic proteins

Article Title: A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2

Article References:
Chu, Y., Chen, S., Yang, M. et al. A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02793-8

Image Credits: AI Generated

Toxoplasma gondii is a protozoan parasite capable of infecting essentially all warm-blooded animals, including humans. Infection typically occurs via ingestion of contaminated food or water, or exposure to cat feces. While generally asymptomatic in healthy individuals, toxoplasmosis can cause severe complications in immunocompromised patients and congenitally infected fetuses, including encephalitis, ocular damage, and fetal developmental abnormalities. Existing treatments are limited by toxicity, side effects, and incomplete parasite eradication, underscoring the urgent need for novel, targeted interventions.

Perillyl alcohol, a naturally occurring monoterpene found in the essential oils of various plants such as lavender, has previously been studied for its anticancer and antimicrobial effects. However, its potential as an anti-parasitic agent against T. gondii marks an exciting advancement. The study by Yu, Song, Li, and colleagues rigorously elucidates how perillyl alcohol disrupts the parasite’s biochemical machinery by modulating the expression of genes pivotal for isoprenylation—a lipid modification essential for proper protein function and cellular viability within T. gondii.

Isoprenylation involves the attachment of isoprenoid groups to target proteins, influencing their membrane localization, protein-protein interactions, and overall activity. In parasites like T. gondii, this process is indispensable for their intracellular lifecycle, enabling survival, replication, and evasion of the host immune system. By interfering with this modification, perillyl alcohol effectively sabotages fundamental parasite processes, rendering it incapable of maintaining the infection.

The researchers employed sophisticated molecular biology techniques to analyze gene expression profiles following treatment with perillyl alcohol. Their data revealed a downregulation of genes encoding enzymes critical for the isoprenylation pathway, including farnesyltransferase and geranylgeranyltransferase components. These enzymes facilitate the enzymatic attachment of isoprenoid units to cysteine residues on substrate proteins, a modification without which the target proteins fail to reach their functional destinations, leading to impaired parasite physiology.

Complementing these genetic analyses, the study utilized in vitro cultures of T. gondii to observe the functional impacts of perillyl alcohol treatment. The compound demonstrated a dose-dependent inhibition of parasite replication and invasion capabilities. Importantly, the selective targeting of parasite-specific isoprenylation machinery suggests a favorable therapeutic index, minimizing host cell toxicity—a critical consideration for drug development.

The implications of these findings extend beyond toxoplasmosis. Isoprenylation is a conserved biochemical process across various pathogenic organisms, including other protozoan parasites such as Plasmodium species responsible for malaria. The realization that perillyl alcohol can modulate this pathway suggests a unified strategy for targeting multiple parasitic infections through a shared vulnerability, heralding a new era of broad-spectrum antiparasitic agents derived from natural products.

Furthermore, this research highlights the burgeoning potential of repurposing phytochemicals traditionally valued for their aromatic and therapeutic properties into potent antiparasitic compounds. The natural origin and previously documented safety profile of perillyl alcohol accelerate its prospects for clinical translation, as pharmacokinetic and toxicological data are increasingly available to support further development.

Given the global health burden posed by toxoplasmosis—especially in regions with limited healthcare infrastructure—therapeutic agents like perillyl alcohol could revolutionize treatment paradigms. This compound’s ability to disrupt parasite-specific pathways while sparing host cells aligns perfectly with the precision medicine approach, promising improved outcomes with reduced adverse effects.

Further investigations are underway to elucidate the full scope of perillyl alcohol’s molecular interactions within the parasite. Understanding how this compound interfaces with the broader metabolic networks of T. gondii will inform the optimization of dosage, delivery methods, and potential synergistic combinations with existing antiparasitic drugs.

Moreover, the team explores the pharmacodynamics and pharmacokinetics of perillyl alcohol in relevant animal models. These studies are paramount to establishing the compound’s efficacy and safety profiles in vivo, paving the way for clinical trials targeting human toxoplasmosis.

Intriguingly, the study also sparks renewed interest in the role of isoprenylation as a drug target in parasitology. Previous efforts to inhibit prenyltransferases have been hampered by issues of specificity and toxicity; however, natural compounds like perillyl alcohol offer unique structural frameworks that can be further refined through medicinal chemistry approaches.

The anti-parasitic spectrum of perillyl alcohol could also offer insights into combination therapies that tackle drug resistance—an emerging problem with current antiparasitic drugs. Targeting essential post-translational modifications represents a novel mechanism distinct from classical antimicrobial actions, potentially reducing the rate at which resistance develops.

In light of these promising data, the global biomedical community eagerly anticipates the translation of these findings from bench to bedside. The integration of molecular parasitology, natural product chemistry, and pharmacology encapsulated in this study sets a precedent for innovative, multidisciplinary approaches to infectious disease management.

To summarize, the research by Yu and colleagues unveils perillyl alcohol as a formidable natural agent against Toxoplasma gondii, operating through a sophisticated mechanism of gene expression modulation within the parasite’s isoprenylation pathway. This discovery not only enhances our understanding of parasite biology but also kindles hope for new, effective therapies against toxoplasmosis and potentially other parasitic diseases.

Subject of Research: Anti-parasitic effect of perillyl alcohol on Toxoplasma gondii via regulation of genes involved in isoprenylation.

Article Title: Perillyl Alcohol Exerts an Anti-Toxoplasma gondii Effect by Regulating the Expression of Genes Related To Isoprenylation.

Article References:
Yu, Y., Song, Q., Li, H. et al. Perillyl Alcohol Exerts an Anti-Toxoplasma gondii Effect by Regulating the Expression of Genes Related To Isoprenylation. Acta Parasit. 70, 130 (2025). https://doi.org/10.1007/s11686-025-01063-6

Image Credits: AI Generated